The Changes of Th17 Cells and the Related Cytokines in the Progression of Human Colorectal Cancers

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2012 Sep 22

PMID 22994684

Citations 17

Authors

Jiansheng Wang

Kaiyu Xu

Jing Wu

Chenghua Luo

Yuchen Li

Xuebin Wu

Hong Gao

Guosheng Feng

Bao-Zhu Yuan

Affiliations

Soon will be listed here.

Abstract

Background: The role of Th17 cells in colorectal tumorigenesis and development still remains unclear, despite the fact that it has been established in the pathogenesis of autoimmune diseases.

Methods: We first analyzed Th17 cells and Treg cells using flow cytometry in the circulation of colorectal adenoma (CRA) and colorectal carcinoma (CRC) patients and healthy controls, and the frequency of Th17 cells in peripheral blood mononuclear cells (PBMCs) stimulated by anti-CD3 plus anti-CD28 and treated by IL-1β, IL-6, and TGF-β in different concentrations. We then detected cytokines IL-1β, IL-6, IL-17A, IL-21, IL-23 or TGF-β by ELISA in sera and supernatants from both normal and tumor tissues cultured ex vivo.

Results: It was found that the percentage of Th17 and Treg cells increased in the circulation of both CRA and CRC patients; the increase of Th17 cells in the circulation occurred in early stages, whereas the increase of Treg cells in the circulation and the increase of Th17 cells in tumor tissues occurred in advanced stages. The subsequent cytokine profiling showed that, along CRC progression, IL-1β, IL-17A and IL-23 underwent a similar change, while IL-6 in CRC exhibited an opposite change, with Th17 cells. In addition, high levels of TGF-β and IL-17A were detected in tumor tissues rather than in normal mucosa. The in vitro experiment further demonstrated that IL-1β, IL-6 or TGF-β modulated Th17 cell expansion in PBMC.

Conclusions: Our study reveals a unique change of Th17 cells, which is regulated possibly by IL-1β, IL-6 and TGF-β in the progression of CRC.

Citing Articles

Inhibition of colorectal cancer in Alzheimer's disease is mediated by gut microbiota via induction of inflammatory tolerance.

Zhang N, Zhang R, Jiang L, Gao Z, Xia W, Ma X Proc Natl Acad Sci U S A. 2024; 121(37):e2314337121.

PMID: 39226363 PMC: 11406296. DOI: 10.1073/pnas.2314337121.

The Role of Inflammatory Cytokines in the Pathogenesis of Colorectal Carcinoma-Recent Findings and Review.

Borowczak J, Szczerbowski K, Maniewski M, Kowalewski A, Janiczek-Polewska M, Szylberg A Biomedicines. 2022; 10(7).

PMID: 35884974 PMC: 9312930. DOI: 10.3390/biomedicines10071670.

Systemic Interleukins' Profile in Early and Advanced Colorectal Cancer.

Czajka-Francuz P, Cison-Jurek S, Czajka A, Kozaczka M, Wojnar J, Chudek J Int J Mol Sci. 2022; 23(1).

PMID: 35008550 PMC: 8745135. DOI: 10.3390/ijms23010124.

Progress in Understanding the IL-6/STAT3 Pathway in Colorectal Cancer.

Lin Y, He Z, Ye J, Liu Z, She X, Gao X Onco Targets Ther. 2020; 13:13023-13032.

PMID: 33376351 PMC: 7762435. DOI: 10.2147/OTT.S278013.

Perioperative changes in lymphocyte subpopulations in patients undergoing surgery for colorectal cancer.

Rubinkiewicz M, Sieminska I, Malczak P, Major P, Baran J, Budzynski A Acta Clin Croat. 2019; 58(2):337-342.

PMID: 31819331 PMC: 6884388. DOI: 10.20471/acc.2019.58.02.18.

References

Bettelli E, Carrier Y, Gao W, Korn T, Strom T, Oukka M . Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006; 441(7090):235-8. DOI: 10.1038/nature04753. View

Center M, Jemal A, Ward E . International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev. 2009; 18(6):1688-94. DOI: 10.1158/1055-9965.EPI-09-0090. View

Berghella A, Contasta I, Pellegrini P, Del Beato T, Adorno D . Are immunological mechanisms involved in colon cancer and are they possible markers for biotherapy improvement?. Cancer Biother Radiopharm. 2006; 21(5):468-87. DOI: 10.1089/cbr.2006.21.468. View

Ye J, Su X, Hsueh E, Zhang Y, Koenig J, Hoft D . Human tumor-infiltrating Th17 cells have the capacity to differentiate into IFN-γ+ and FOXP3+ T cells with potent suppressive function. Eur J Immunol. 2011; 41(4):936-51. DOI: 10.1002/eji.201040682. View

Yang L, Anderson D, Baecher-Allan C, Hastings W, Bettelli E, Oukka M . IL-21 and TGF-beta are required for differentiation of human T(H)17 cells. Nature. 2008; 454(7202):350-2. PMC: 2760130. DOI: 10.1038/nature07021. View

Leslie A, Carey F, Pratt N, Steele R . The colorectal adenoma-carcinoma sequence. Br J Surg. 2002; 89(7):845-60. DOI: 10.1046/j.1365-2168.2002.02120.x. View

Cui G, Goll R, Olsen T, Steigen S, Husebekk A, Vonen B . Reduced expression of microenvironmental Th1 cytokines accompanies adenomas-carcinomas sequence of colorectum. Cancer Immunol Immunother. 2006; 56(7):985-95. PMC: 11030272. DOI: 10.1007/s00262-006-0259-y. View

Ogino S, Nosho K, Irahara N, Meyerhardt J, Baba Y, Shima K . Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin Cancer Res. 2009; 15(20):6412-20. PMC: 2771425. DOI: 10.1158/1078-0432.CCR-09-1438. View

Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R . Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005; 353(25):2654-66. DOI: 10.1056/NEJMoa051424. View

10.

Pellegrini P, Berghella A, Contasta I, Del Beato T, Adorno D . The study of a patient's immune system may prove to be a useful noninvasive tool for stage classification in colon cancer. Cancer Biother Radiopharm. 2006; 21(5):443-67. DOI: 10.1089/cbr.2006.21.443. View

11.

Acosta-Rodriguez E, Napolitani G, Lanzavecchia A, Sallusto F . Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol. 2007; 8(9):942-9. DOI: 10.1038/ni1496. View

12.

Zhou L, Lopes J, Chong M, Ivanov I, Min R, Victora G . TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature. 2008; 453(7192):236-40. PMC: 2597437. DOI: 10.1038/nature06878. View

13.

Shanahan F, Brogan M, Targan S . Human mucosal cytotoxic effector cells. Gastroenterology. 1987; 92(6):1951-7. DOI: 10.1016/0016-5085(87)90629-9. View

14.

Miossec P, Korn T, Kuchroo V . Interleukin-17 and type 17 helper T cells. N Engl J Med. 2009; 361(9):888-98. DOI: 10.1056/NEJMra0707449. View

15.

Shen L, Wang J, Shen D, Yuan X, Dong P, Li M . CD4(+)CD25(+)CD127(low/-) regulatory T cells express Foxp3 and suppress effector T cell proliferation and contribute to gastric cancers progression. Clin Immunol. 2009; 131(1):109-18. DOI: 10.1016/j.clim.2008.11.010. View

16.

Kryczek I, Wei S, Zou L, Altuwaijri S, Szeliga W, Kolls J . Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol. 2007; 178(11):6730-3. DOI: 10.4049/jimmunol.178.11.6730. View

17.

Stritesky G, Yeh N, Kaplan M . IL-23 promotes maintenance but not commitment to the Th17 lineage. J Immunol. 2008; 181(9):5948-55. PMC: 2678905. DOI: 10.4049/jimmunol.181.9.5948. View

18.

Hoechst B, Gamrekelashvili J, Manns M, Greten T, Korangy F . Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells. Blood. 2011; 117(24):6532-41. DOI: 10.1182/blood-2010-11-317321. View

19.

Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C . Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006; 313(5795):1960-4. DOI: 10.1126/science.1129139. View

20.

Reimund J, Wittersheim C, Dumont S, Muller C, KENNEY J, Baumann R . Increased production of tumour necrosis factor-alpha interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease. Gut. 1996; 39(5):684-9. PMC: 1383392. DOI: 10.1136/gut.39.5.684. View